Close Menu

This story has been updated to reflect that the BioLegend-VIB partnership will focus on deployment rather than development of a single-cell technology.

NEW YORK (GenomeWeb) – Antibody provider BioLegend announced today a partnership with the Belgian life science research institute VIB to deploy a single-cell multi-omics technology.

Under the partnership, the parties will test and implement BioLegend's TotalSeq antibodies as part of a workflow combing single-cell proteomics with single-cell transcriptomics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.